

Petra Hillmann

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1745438/publications.pdf>

Version: 2024-02-01

5
papers

323
citations

1683354

5
h-index

2053342

5
g-index

5
all docs

5
docs citations

5
times ranked

538
citing authors

#	ARTICLE	IF	CITATIONS
1	Novel brain permeant mTORC1/2 inhibitors are as efficacious as rapamycin or everolimus in mouse models of acquired partial epilepsy and tuberous sclerosis complex. <i>Neuropharmacology</i> , 2020, 180, 108297.	2.0	23
2	PI3K/mTOR Pathway Inhibition: Opportunities in Oncology and Rare Genetic Diseases. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5792.	1.8	65
3	Discovery and Preclinical Characterization of 5-[4,6-Bis({3-oxa-8-azabicyclo[3.2.1]octan-8-yl})-1,3,5-triazin-2-yl]-4-(difluoromethyl)pyridin-2-amine (PQR620), a Highly Potent and Selective mTORC1/2 Inhibitor for Cancer and Neurological Disorders. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 10084-10105.	2.9	62
4	The novel, catalytic mTORC1/2 inhibitor PQR620 and the PI3K/mTORC1/2 inhibitor PQR530 effectively cross the blood-brain barrier and increase seizure threshold in a mouse model of chronic epilepsy. <i>Neuropharmacology</i> , 2018, 140, 107-120.	2.0	64
5	5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a Potent, Brain-Penetrant, Orally Bioavailable, Pan-Class I PI3K/mTOR Inhibitor as Clinical Candidate in Oncology. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 7524-7538.	2.9	109